Viral protease inhibitors (Q34892265)

5 August 2017

1 reference

title

Viral protease inhibitors (English)

1 reference

5 August 2017

Ronald Swanstrom

1 reference

5 August 2017

Celia Schiffer

1 reference

5 August 2017

Jeffrey Anderson

1 reference

5 August 2017

Sook-Kyung Lee

series ordinal

1 reference

5 August 2017

publication date

1 January 2009

1 reference

Handbook of experimental pharmacology

5 August 2017

published in

1 reference

5 August 2017

issue

189

1 reference

5 August 2017

page(s)

85-110

1 reference

L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor

5 August 2017

cites work

1 reference

12 December 2020

Peptide-based inhibitors of the hepatitis C virus serine protease

1 reference

12 December 2020

Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication

1 reference

12 December 2020

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

12 December 2020

A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease

1 reference

12 December 2020

Phase II, randomized, double-blind, placebo-controlled studies of ruprintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers

1 reference

12 December 2020

Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor

1 reference

12 December 2020

Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill

1 reference

12 December 2020

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

1 reference

12 December 2020

Structure of the human cytomegalovirus protease catalytic domain reveals a novel serine protease fold and catalytic triad.

1 reference

12 December 2020

Activity of purified hepatitis C virus protease NS3 on peptide substrates

1 reference

12 December 2020

Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein

1 reference

12 December 2020

Characterization and inhibition of SARS-coronavirus main protease

1 reference

12 December 2020

Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin-like serine proteinases

1 reference

12 December 2020

Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments

1 reference

12 December 2020

Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases

1 reference

12 December 2020

Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase.

1 reference

12 December 2020

Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.

1 reference

12 December 2020

1 reference

12 December 2020

Dimerization of the human cytomegalovirus protease: kinetic and biochemical characterization of the catalytic homodimer

1 reference

12 December 2020

In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease

1 reference

12 December 2020

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

1 reference

12 December 2020

In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease

1 reference

12 December 2020

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

1 reference

12 December 2020

Ritonavir-Boosted Tipranavir Demonstrates Superior Efficacy to Ritonavir-Boosted Protease Inhibitors in Treatment-Experienced HIV-Infected Patients: 24-Week Results of the RESIST-2 Trial

1 reference

12 December 2020

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

12 December 2020

Pharmacokinetic enhancement of protease inhibitor therapy

1 reference

12 December 2020

Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient

1 reference

12 December 2020

Structural characterization of the interactions of optimized product inhibitors with the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein by NMR and modelling studies

1 reference

12 December 2020

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

1 reference

12 December 2020

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

12 December 2020

Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain

1 reference

12 December 2020

Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes

1 reference

12 December 2020

Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects

1 reference

12 December 2020

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

12 December 2020

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

1 reference

12 December 2020

Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bio

1 reference

12 December 2020

A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group

1 reference

12 December 2020

Potent peptide inhibitors of human hepatitis C virus NS3 protease are obtained by optimizing the cleavage products

1 reference

12 December 2020

Synergy of Small Molecular Inhibitors of Hepatitis C Virus Replication Directed at Multiple Viral Targets

1 reference

12 December 2020

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

1 reference

12 December 2020

Association of a novel human immunodeficiency virus type 1 protease substrate cleft mutation, L23I, with protease inhibitor therapy and in vitro drug resistance

1 reference

12 December 2020

Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor

1 reference

12 December 2020

Structure-based discovery of Tipranavir disodium (PNU-140690E): a potent, orally bioavailable, nonpeptidic HIV protease inhibitor

1 reference

12 December 2020

Enzymatic activities of human cytomegalovirus maturational protease assemblin and its precursor (pPR, pUL80a) are comparable: [corrected] maximal activity of pPR requires self-interaction through its scaffolding domain

1 reference

12 December 2020

Structure-based inhibitors of HIV-1 protease

1 reference

12 December 2020

Progress for dengue virus diseases. Towards the NS2B-NS3pro inhibition for a therapeutic-based approach

1 reference

12 December 2020

Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus

1 reference

12 December 2020

A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir).

1 reference

12 December 2020

In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease

1 reference

12 December 2020

Peptidomimetic inhibitors of HIV protease

1 reference

12 December 2020

Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus.

1 reference

12 December 2020

Rhinovirus chemotherapy

1 reference

12 December 2020

A herpesvirus maturational proteinase, assemblin: identification of its gene, putative active site domain, and cleavage site

1 reference

12 December 2020

Conserved mode of peptidomimetic inhibition and substrate recognition of human cytomegalovirus protease

1 reference

12 December 2020

The NS3/4A proteinase of the hepatitis C virus: unravelling structure and function of an unusual enzyme and a prime target for antiviral therapy

1 reference

12 December 2020

HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance

1 reference

12 December 2020

Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients

1 reference

12 December 2020

Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism

1 reference

12 December 2020

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

1 reference

12 December 2020

Computational design and experimental study of tighter binding peptides to an inactivated mutant of HIV-1 protease

1 reference

12 December 2020

Susceptibility to PNU-140690 (Tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors

1 reference

12 December 2020

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

1 reference

12 December 2020

A mechanistic view of enzyme inhibition and peptide hydrolysis in the active site of the SARS-CoV 3C-like peptidase

1 reference

12 December 2020

Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959.

1 reference

12 December 2020

Safety and activity of saquinavir in HIV infection

1 reference

12 December 2020

In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor

1 reference

12 December 2020

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Three-dimensional structure of human cytomegalovirus protease

1 reference

12 December 2020

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

12 December 2020

Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain

1 reference

12 December 2020

Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides

1 reference

12 December 2020

Substrate envelope and drug resistance: crystal structure of RO1 in complex with wild-type human immunodeficiency virus type 1 protease

1 reference

12 December 2020

A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection

1 reference

12 December 2020

Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

1 reference

12 December 2020

An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis C virus RNA.

1 reference

12 December 2020

Structural and biochemical studies of inhibitor binding to human cytomegalovirus protease

1 reference

12 December 2020

ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease

1 reference

12 December 2020

The herpes simplex virus 1 gene encoding a protease also contains within its coding domain the gene encoding the more abundant substrate

1 reference

12 December 2020

Design of wide-spectrum inhibitors targeting coronavirus main proteases

1 reference

12 December 2020

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

12 December 2020

Advances in the development of new therapeutic agents targeting the NS3-4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus

1 reference

12 December 2020

Product inhibition of the hepatitis C virus NS3 protease

1 reference

12 December 2020

Identification of a novel coronavirus in bats

1 reference

12 December 2020

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design

1 reference

12 December 2020

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

1 reference

12 December 2020

Novel binding mode of highly potent HIV-proteinase inhibitors incorporating the (R)-hydroxyethylamine isostere

1 reference

12 December 2020

Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format

1 reference

12 December 2020

Design of mutation-resistant HIV protease inhibitors with the substrate envelope hypothesis

1 reference

12 December 2020

Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease

1 reference

12 December 2020

Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes

1 reference

12 December 2020

Long-term (4 years) efficacy of lopinavir/ritonavir monotherapy for maintenance of HIV suppression.

1 reference

12 December 2020

Covariation of amino acid positions in HIV-1 protease

1 reference

12 December 2020

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

12 December 2020

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

12 December 2020

Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor

1 reference

12 December 2020

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease

1 reference

12 December 2020

Pharmacology of antiretroviral drugs.

1 reference

12 December 2020

Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro

1 reference

12 December 2020

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

1 reference

12 December 2020

Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial

1 reference

12 December 2020

Unique fold and active site in cytomegalovirus protease

1 reference

12 December 2020

Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase

1 reference

12 December 2020

Protease inhibitors and their peptidomimetic derivatives as potential drugs

1 reference

12 December 2020

1 reference

12 December 2020

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

12 December 2020

Active human cytomegalovirus protease is a dimer.

1 reference

12 December 2020

ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.

1 reference

12 December 2020

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

1 reference

12 December 2020

Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus

1 reference

12 December 2020

Herpesvirus protease inhibition by dimer disruption

1 reference

12 December 2020

Crystal structures of the main peptidase from the SARS coronavirus inhibited by a substrate-like aza-peptide epoxide.

1 reference

12 December 2020

10.1007/978-3-540-79086-0_4

Identifiers

DOI

1 reference

5 August 2017

1 reference